Organization
University of North Carolina at Chapel Hill
26 abstracts
Abstract
Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).Org: New York University School of Medicine, The Ohio State University Comprehensive Cancer Center, Duke University Medical Center, Northwestern University, University of Colorado Comprehensive Cancer Center,
Abstract
Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance).Org: Columbus, OH, GZA-ZNA Hospitals, Joan and Sanford I Weill Medical College of Cornell University, Weill Cornell Medicine, New York, NY,
Abstract
Racial disparities and survival outcome of patients with locally advanced cervix cancer in the international randomised phase 3 OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274).Org: NHMRC Clinical Trials Centre, The University of Sydney, Louisiana State University Health Sciences Center, Department of Gynecologic Oncology, University of California, Los Angeles,
Abstract
The impact of self-reported social determinants of health (SDOH) on patient engagement and symptom burden across a remote patient monitoring (RPM) pathway in 42 European hospitals.Org: Cancer Survivorship Program, INSERM 981, Gustave Roussy, Villejuif, France, INSERM Unit 981, Gustave Roussy Cancer Center, Villejuif, France, Patient Pathway Division,
Abstract
Surgically targeted radiation therapy (STaRT) for recurrent glioblastoma: Initial outcomes from a prospective multicenter registry.Org: Miami Cancer Institute - Baptist Health South Florida, Baptist Health South Florida, GT Medical Technologies, University of Minnesota Medical Center, University of Texas Southwestern Medical Center,
Abstract
Impact of race and age on intrinsic subtype distribution and treatment decisions in metastatic breast cancer: Preliminary analysis of HARMONY (LCCC1829).Org: University of North Carolina at Chapel Hill, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, University of North Carolina School of Medicine, University of Milano, European Institute of Oncology, Division of Early Drug Development, Lineberger Comprehensive Cancer Center,
Abstract
Distribution and outcomes of HER2-low and HER2-zero metastatic breast cancer in Black and younger women.Org: UNC Lineberger Comprehensive Cancer Center/University of Milan, University of North Carolina at Chapel Hill, Department of Medicine, University of North Carolina at Chapel Hill, University of North Carolina/Lineberger Comprehensive Cancer Center, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC,
Abstract
Phase I/II study of stereotactic radiosurgery with concurrent olaparib followed by adjuvant durvalumab and physician’s choice systemic therapy in patients with breast cancer brain metastases.Org: University of North Carolina at Chapel Hill, Memorial Sloan Kettering Cancer Center, University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center, Dana-Farber Cancer Institute,
Abstract
ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery.Org: Dana-Farber Cancer Institute, University of Pennsylvania, The Cancer Institute Hospital of JFCR, Tokyo, Japan, University of California Comprehensive Cancer Center, University of North Carolina at Chapel Hill,
Abstract
Novel use of alternate (Alt) response (Rp) criteria (Cr) for early prediction of outcomes in pancreatic (P) neuroendocrine tumors (NETs): Utilizing banked imaging data from the ECOG-ACRIN E2211 study.Org: Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, Yale Cancer Center, Yale School of Medicine, New Haven, CT, New Haven, CT,
Abstract
Ultra-sensitive, tumor-informed ctDNA profiling in patients with gastroesophageal cancer and treated with pembrolizumab and longitudinal ctDNA kinetics.Org: Duke University Medical Center, Personalis, Inc., University of North Carolina at Chapel Hill, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,
Abstract
Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial.Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Alliance Statistics and Data Center, Mayo Clinic, University of North Carolina at Chapel Hill,
Abstract
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.Org: SOLTI Cancer Research Group, Ohio State University Comprehensive Cancer Center, Novartis Pharmaceuticals, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, University of North Carolina School of Medicine,
Abstract
Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial.Org: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, University of Chicago Comprehensive Cancer Center, Chicago, IL, University of Michigan Rogel Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Lineberger Comprehensive Cancer Center,
Abstract
Phase 1b/2 trial of pepinemab plus avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma.Org: University of Rochester Cancer Center & Wilmot Cancer Institute, Vaccinex, Inc., University of North Carolina at Chapel Hill,
Abstract
Crossing the US-Mexico border for cancer care: Which treatments are more sought-after?Org: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, University of North Carolina at Chapel Hill, Vanderbilt University Medical Center, ISSSTE CMN 20 De Noviembre, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico,
Abstract
National survey of financial burdens and experience among patients with cancer receiving charitable co-pay assistance.Org: Massachusetts General Hospital, Fox Chase Cancer Center, Temple University Health System, HealthWell Foundation, University of North Carolina at Chapel Hill,
Abstract
Pursuing cancer treatment across the US-Mexico border: Motivations and barriers.Org: Vanderbilt University Medical Center, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, University of North Carolina at Chapel Hill, ISSSTE CMN 20 De Noviembre, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico,
Abstract
Patient-level interventions to increase guideline concordant treatment among Black breast cancer patients: Can they close the racial gap in survival after diagnosis?Org: University of North Carolina at Chapel Hill, University of North Carolina School of Medicine, The University of North Carolina at Chapel Hill,
Abstract
Etiology and outcomes of neutropenic fever in Malawi: A prospective, observational cohort.Org: Georgetown University School of Medicine, University of North Carolina Project-Malawi, University of North Carolina at Chapel Hill,
Abstract
Intralesional therapy, limb infusion/perfusion, and immune checkpoint inhibitors as first-line therapy in surgically unresectable melanoma in-transit metastases.Org: H. Lee Moffitt Cancer Center and Research Institute, Moffitt Cancer Center, University of North Carolina at Chapel Hill, Mayo Clinic, Netherlands Cancer Institute,
Abstract
Functional status and therapy receipt among older adults with multiple myeloma.Org: University of North Carolina School of Medicine, University of North Carolina at Chapel Hill, University of North Carolina School of Nursing, UNC Gillings School of Global Public Health,
Abstract
Using EHR data and machine learning approach to facilitate the identification of patients with lung cancer from a pan-cancer cohort.Org: Mayo Clinic, University of Bergen, Johns Hopkins University Bloomberg School of Public Health, University of North Carolina at Chapel Hill,
Abstract
Enhanced detection and characterization of targetable EGFR and ERBB2 exon20 insertion mutations in urothelial carcinoma.Org: University of North Carolina School of Medicine, UNC Hosps, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill,
Abstract
Transnational utilization of diagnostic studies across the US-Mexico border.Org: University of North Carolina at Chapel Hill, Vanderbilt University Medical Center, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, ISSSTE CMN 20 De Noviembre, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico,
Abstract
A phase iii randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept or placebo on standard of care in patients with active class iii or iv lupus nephritisOrg: Northwell Health, New Hyde Park, NY, University of North Carolina at Chapel Hill, University of California San Francisco, Keio University School of Medicine, Hospital Fernández,